KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) Revenue (2016 - 2025)

Edwards Lifesciences has reported Revenue over the past 17 years, most recently at $1.6 billion for Q4 2025.

  • Quarterly results put Revenue at $1.6 billion for Q4 2025, up 13.26% from a year ago — trailing twelve months through Dec 2025 was $6.1 billion (up 11.55% YoY), and the annual figure for FY2025 was $6.1 billion, up 11.55%.
  • Revenue for Q4 2025 was $1.6 billion at Edwards Lifesciences, up from $1.6 billion in the prior quarter.
  • Over the last five years, Revenue for EW hit a ceiling of $1.6 billion in Q4 2025 and a floor of $429.9 million in Q4 2022.
  • Median Revenue over the past 5 years was $1.3 billion (2022), compared with a mean of $1.3 billion.
  • Biggest five-year swings in Revenue: plummeted 67.67% in 2022 and later soared 194.58% in 2023.
  • Edwards Lifesciences' Revenue stood at $1.3 billion in 2021, then plummeted by 67.67% to $429.9 million in 2022, then soared by 194.58% to $1.3 billion in 2023, then grew by 9.43% to $1.4 billion in 2024, then increased by 13.26% to $1.6 billion in 2025.
  • The last three reported values for Revenue were $1.6 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.5 billion (Q2 2025) per Business Quant data.